HER2 Support Group Forums - View Single Post

runtolive · 03-03-2008, 06:57 AM

the next drug in line is coming from genentech.. its called TRASTUZUMAB-DM1..

its actually herceptin conjugated with a toxin ( poison) ..DM1 ... while herceptin is typically only active in about 25% of its patients.. the conjugated version actually showed an 80% response rate.. 7 patients had stable disease and 5 patients showed a partial response.. out of 15 total patients.. genentech reported these results at the SABC in san antonio in december 2007. genentech is currently running two separate tras-dm1 trials... a phase 2 trial dosed every 3 weeks.. and a phase 1 trial dosed once a week.. at least 5 women i know of our involved in this trial with a 6th lady scheduled to begin in 2 weeks..

http://clinicaltrials.gov/ct2/show/N...ow_locs=Y#locn

this is a link to the every 3 week trial..

run to live

03-03-2008, 06:57 AM	#20
runtolive Senior Member Join Date: Nov 2007 Posts: 210	the next drug in line is coming from genentech.. its called TRASTUZUMAB-DM1.. its actually herceptin conjugated with a toxin ( poison) ..DM1 ... while herceptin is typically only active in about 25% of its patients.. the conjugated version actually showed an 80% response rate.. 7 patients had stable disease and 5 patients showed a partial response.. out of 15 total patients.. genentech reported these results at the SABC in san antonio in december 2007. genentech is currently running two separate tras-dm1 trials... a phase 2 trial dosed every 3 weeks.. and a phase 1 trial dosed once a week.. at least 5 women i know of our involved in this trial with a 6th lady scheduled to begin in 2 weeks.. http://clinicaltrials.gov/ct2/show/N...ow_locs=Y#locn this is a link to the every 3 week trial.. run to live